DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $146,627 | +0.8% | 591 | -2.5% | 0.02% | +10.0% |
| Q2 2023 | $145,440 | -8.4% | 606 | -3.8% | 0.02% | -16.7% |
| Q1 2023 | $158,785 | +6.6% | 630 | +12.3% | 0.02% | -4.0% |
| Q4 2022 | $148,901 | +41.8% | 561 | +38.2% | 0.02% | +13.6% |
| Q3 2022 | $105,000 | +1.9% | 406 | 0.0% | 0.02% | +10.0% |
| Q2 2022 | $103,000 | -13.4% | 406 | 0.0% | 0.02% | -9.1% |
| Q1 2022 | $119,000 | -11.9% | 406 | -1.0% | 0.02% | -15.4% |
| Q4 2021 | $135,000 | +1.5% | 410 | -6.0% | 0.03% | -7.1% |
| Q3 2021 | $133,000 | +13.7% | 436 | 0.0% | 0.03% | +12.0% |
| Q2 2021 | $117,000 | +19.4% | 436 | 0.0% | 0.02% | +13.6% |
| Q1 2021 | $98,000 | +1.0% | 436 | 0.0% | 0.02% | -8.3% |
| Q4 2020 | $97,000 | +3.2% | 436 | 0.0% | 0.02% | -17.2% |
| Q3 2020 | $94,000 | -40.5% | 436 | -51.4% | 0.03% | -45.3% |
| Q2 2020 | $158,000 | +54.9% | 898 | +21.8% | 0.05% | +26.2% |
| Q1 2020 | $102,000 | -10.5% | 737 | -1.5% | 0.04% | -27.6% |
| Q4 2019 | $114,000 | – | 748 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |